期刊文献+

肺动脉高压诊治研究进展 被引量:7

下载PDF
导出
摘要 肺动脉高压(Pulmonary artery hypertension,PAH)不是一种疾病的诊断,可由许多心、肺和肺血管疾病引起。根据美国国立卫生研究院制定的标准,若在静息状态下心导管测定肺动脉平均压(MPAP)大于25mmHg。
出处 《陕西医学杂志》 CAS 2012年第1期110-112,126,共4页 Shaanxi Medical Journal
  • 相关文献

参考文献2

二级参考文献36

  • 1荆志成,徐希奇.肺动脉高压现代分类和诊断策略[J].中华心血管病杂志,2004,32(12):1160-1162. 被引量:40
  • 2荆志成.六分钟步行距离试验的临床应用[J].中华心血管病杂志,2006,34(4):381-384. 被引量:98
  • 3Rubin LJ. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest,2004,126(1 Suppl) :7S-10S.
  • 4Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol, 2004,43 (12 Suppl S) :5S-12S.
  • 5Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol, 2004, 43(12 Suppl S) :40S-47S.
  • 6Jing ZC, Xu XQ, Han ZY, et al. Registry and Survival Study in Chinese Patients with Idiopathic and Familial Pulmonary Arterial Hypertension. Chest, 2007,132 ( 2 ) :373-379.
  • 7Sitbon O, Humbert M, JaYs X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation, 2005,111 (23): 3105-3111.
  • 8Proceeding of 3rd World Symposium on Pulmonary Arterial Hypertension. Venice, Italy, June 23-25, 2003. J Am Coll Cardiol, 2004,43(2 Suppl S) : 1S-90S.
  • 9Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest, 2004, 126( Suppl 1 ) : 1 S-92S.
  • 10Galie N, Torbicki A, Barst A, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J, 2004,25 ( 24 ) : 2243-2278.

共引文献285

同被引文献45

  • 1荆志成.2010年中国肺高血压诊治指南[J].中国医学前沿杂志(电子版),2011,3(2):62-81. 被引量:117
  • 2吴凯,许英,赖萍.益气活血法降低肺心病肺动脉高压即刻效应观察[J].新中医,2007,39(7):25-26. 被引量:3
  • 3世界卫生组织.疾病和有关健康问题的国际统计分类(ICD-10)[M].懂景五,主译.2版.北京:人民卫生出版社,2008:6.
  • 4Dorfmuller P, Perros F, Balabanian K, et al. Inflamma- tion in pulmonary arterial hypertension[J]. Eur Respir J, 2003,22(2) : 358-363.
  • 5Machado FS, A[iberti J. Impact of lipoxin-mediated regu- lation on immune response to infectious disease[J]. Im- munol Res, 2006,35(3) :209-218.
  • 6Baker N, O'Meara SJ, Scannell M, et al. Lipoxin A4: anti-inflammatory and anti-angiogenic impact on endothe- lial cells[J]. J Immunol, 2009,182(6) :3819-3826.
  • 7Price LC, Wort SJ, Perros F, etal. Inflammation in pul- monary arterial hypertension[J]. Chest, 2012,141 ( 1 ) : 210-221.
  • 8George J, Sun J, I2Armiento J. Transgenic expression of human matrix metalloproteinase-1 attenuates pulmonary arterial hypertension in mie[J]. Clin Sci (Lond), 2012, 122(2) :83-92.
  • 9Gong J, Guo S, Li HB, etal. BML-111, a lipoxin recep- tor agonist, protects haemorrhagic shock-induced acute lung injury in rats[J]. Resuscitation, 2012,83 (2) : 902- 912.
  • 10刘珍才,蔡玉桂,梁志鹏,等.医学综合征与国际疾病分类[M].海南:南海出版公司,2004.

引证文献7

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部